Scandinavian Biopharma has entered into an agreement with Flynn Pharma for the viper antivenom ViperaTAb.
Under the agreement, Scandinavian Biopharma will have exclusive rights to service and make ViperaTAb available for emergency use in the Nordics, Baltic States and Germany.
“We are very pleased to strengthen our portfolio with an important antivenom for Northern Europe” says Björn Sjöstrand, CEO at Scandinavian Biopharma.
ViperaTAb is not registered in the European Union but is available under special permission.
Source: Scandinavian Biopharma
Photo: Kristofer Sandberg